Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 13Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Head and Neck Neoplasms 7Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Nasopharyngeal Carcinoma 6Carcinoma, Squamous Cell 5Esophageal Squamous Cell Carcinoma 3Carcinoma 3Thymoma 2Stomach Neoplasms 2Neoplasms by Site 2Neoplasms 2NSCLC 2Lymphoma 2Hypopharyngeal Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Urinary Bladder Neoplasms 1Thrombocytopenia 1Small Cell Lung Carcinoma 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1SCLC, Extensive Stage 1Resectable Esophageal Cancer 1Rectal Malignant Neoplasms 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sinonasal Squamous Cell Carcinoma × Chemoradiotherapy × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡